NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
GOCO Shareholders Click Here: https://www.zlk.com/pslra-1/gohealth-inc-information-request-form?prid=11091&wire=1
CACC Shareholders Click Here: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=11091&wire=1
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11091&wire=1
* ADDITIONAL INFORMATION BELOW *
GoHealth, Inc. (NASDAQ:GOCO)
The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.
Lead Plaintiff Deadline : November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gohealth-inc-information-request-form?prid=11091&wire=1
According to the filed complaint, (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.
Credit Acceptance Corporation (NASDAQ:CACC)
CACC Lawsuit on behalf of: investors who purchased November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline : December 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=11091&wire=1
According to the filed complaint, during the class period, Credit Acceptance Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.
Biogen Inc. (NASDAQ:BIIB)
BIIB Lawsuit on behalf of: investors who purchased October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11091&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP